factually
Index/Organizations/Shingrix

Shingrix

Recombinant subunit vaccine by GSK

Fact-Checks

4 results
Dec 20, 2025
Most Viewed

How effective is shingles vaccine

The currently recommended recombinant zoster vaccine (RZV, marketed as Shingrix) is highly effective at preventing shingles and its common complication postherpetic neuralgia, with clinical trials sho...

Jan 17, 2026
Most Viewed

Safety of shingles vaccine

The currently recommended shingles vaccine, Shingrix (recombinant zoster vaccine, RZV), has a strong safety and effectiveness record in clinical trials and large real‑world studies, with common short‑...

Jan 17, 2026

What substance was used in control group for shingrix trials

The pivotal phase 3 ZOE-50 and ZOE-70 trials that supported SHINGRIX licensing were randomized, observer‑blind, placebo‑controlled studies — participants were assigned to receive two doses of the reco...

Dec 20, 2025

Does GSK release all company held data for Shinto’s for independent inspection

GSK does not appear to make "all company-held data" for Shingrix publicly available for independent inspection; instead the company provides comprehensive datasets and analyses to regulators and publi...